Brief: Biomea Fusion Announces Positive Topline Results From Ongoing Phase II COVALENT-111 Study
17/12/2024 14:12
Dec 17 (Reuters) - Biomea Fusion Inc BMEA.O :
* BIOMEA FUSION ANNOUNCES POSITIVE TOPLINE RESULTS FROM
ONGOING
PHASE II COVALENT-111 STUDY IN PATIENTS WITH TYPE 2 DIABETES
* BIOMEA FUSION INC - ICOVAMENIB MEETS PRIMARY ENDPOINT WITH
SIGNIFICANT REDUCTION IN HBA1C
* BIOMEA FUSION INC - ICOVAMENIB WELL-TOLERATED WITH NO
SERIOUS
ADVERSE EVENTS
Source text: ID:nGNX5XcnRR
Further company coverage: BMEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes